The Global Coagulation factor concentrate market is estimated to grow at a significant CAGR during the forecast period. Hemophilia is best treated by replacing the missing blood clotting factor, which allows the blood to clot properly. This is typically done by injecting clotting factor concentrates, which are therapeutic products, into a person’s vein. Doctors typically prescribe treatment agents for either episodic or prophylactic care. Prophylactic care is used to prevent bleeding episodes from arising. Episodic treatment is used to stop a patient’s bleeding episodes. By transforming severe haemophilia (factor VIII or IX less than 1%) into a clinically milder version of the disease, clotting factor concentrate prophylaxis aims to preserve joint function. The single most important predictor of cost in haemophilia treatment is the use of clotting factor concentrates.
A full report of Coagulation factor concentrate Market is available at: https://www.omrglobal.com/industry-reports/coagulation-factor-concentrate-market
The demand for recombinant and plasma-derived factor VIII and factor IX, which are used to treat haemophilia, is increasing due to an increase in the number of hemophilic patients around the globe. In addition, the market is expected to expand as the rate of haemophilia diagnosis rises and the usage of prophylactic treatment for haemophilia increases. However, the high cost of recombinant products, serious side effects associated with plasma-derived therapies, and strict regulatory regulations are all stifling the global haemophilia market’s growth. The increasing the prevalence of haempophilia snd prophylactic treatment for haemophila increases will drive the coagulation factor concentrate market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/coagulation-factor-concentrate-market
According to Centre for disease control prevention (CDC) in the United States, around 70% of people with haemophilia get multidisciplinary, comprehensive care through a network of federally sponsored haemophilia treatment facilities. Hemophilia A affects one out of every 5,000 male babies born. Every year, about 400 infants are born with haemophilia A. People who got care at haemophilia treatment facilities had 40% reduced mortality and hospitalisation rates for bleeding problems.
Market Coverage
- The market number available for – 2020-2026
- Base year- 2020
- Forecast period- 2021-2026
- Segment covered
o By Type
o BY Application
- Region covered
o North America
o Europe
o Asia-Pacific
o Rest of the world
- Competitive Landscape- Medscape., CSL Behring, Octapharma.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Market Segmentation
By Type
- Coagulation Factor IX
- Coagulation Factor XIII
- Others
By Application
- Hospitals and Clinics
- Research Laboratories
- Academic Institutions
Company Profiles
- Medscape.
- CSL Behring
- Octapharma
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
